A Study for the Neoadjuvant Treatment of Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE4
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
- Status
- SUSPENDED
- Phase
- PHASE1
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors
- Status
- TEMPORARILY_NOT_AVAILABLE
- Phase
- N/A
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
- Status
- RECRUITING
- Phase
- PHASE3
......SMARTEST Trial......
- Status
- COMPLETED
- Phase
- PHASE2
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Genotype-guided Treatment in DLBCL
- Status
- RECRUITING
- Phase
- PHASE3
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2